Dermatitis Artefacta Medication

  • Author: John YM Koo, MD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Jan 25, 2012
 

Medication Summary

Topical antimicrobials are the most commonly prescribed medication; however, topical agents alone have shown limited efficacy. In many instances, treating the underlying psychiatric disorder with antidepressants, antianxiety drugs, and antipsychotic agents is necessary.[17, 18] Analgesics should be avoided because of the high probability for dependence and addiction.

Next

Topical antimicrobials

Class Summary

Self-inflicted lesions are often accompanied by a localized skin infection.

Neomycin/polymyxin B/bacitracin topical (AK-Spore Ointment, Neocin, Neosporin)

 

Bacitracin prevents transfer of mucopeptides into growing cell wall, inhibiting bacterial growth.

Neomycin is used for treatment of minor infections; inhibits bacterial protein synthesis and growth. Polymyxin B disrupts bacterial cytoplasmic membrane, permitting leakage of intracellular constituents and causing inhibition of bacterial growth.

Fusidic acid (Fucidin, Fusidin, Fusidin Leo)

 

Topical antibacterial that inhibits bacterial protein synthesis, causing bacterial death.

Previous
Next

Oral antibiotics

Class Summary

For impetiginized skin lesions.

Cephalexin (Keflex, Keftab, Biocef)

 

First-generation cephalosporin that inhibits bacterial replication by inhibiting bacterial cell wall synthesis. Bactericidal and effective against rapidly growing organisms forming cell walls. Resistance occurs by alteration of penicillin-binding proteins. Effective for treatment of infections caused by streptococci or staphylococci, including penicillinase-producing staphylococci. May use to initiate therapy when streptococcal or staphylococcal infection is suspected. Used orally when outpatient management is indicated. Recommended for impetigo caused by Staphylococcus aureus resistant to erythromycin. Primary activity against skin florae. Used for skin infections or prophylaxis in minor procedures.

Erythromycin (E-Mycin, Eryc, Ery-Tab)

 

Use with hypersensitivity or contraindication to penicillin or cephalexin. May result in GI upset, prompting prescription of an alternative macrolide or a change to tid dosing. Covers most potential etiologic agents, including Mycoplasma species.

Less active against Haemophilus influenzae. Although 10 d seems to be a standard course of treatment, treating until patient has been afebrile for 3-5 d seems more rational. Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. For treatment of staphylococcal and streptococcal infections.

In children, age, weight, and severity of infection determine proper dosage. When bid dosing is desired, half the total daily dose may be taken q12h. For more severe infections, double the dose. Has added advantage of being a good anti-inflammatory agent by inhibiting migration of polymorphonuclear leukocytes.

Previous
Next

Selective serotonin reuptake inhibitors

Class Summary

First-line therapy for depression. Other medications in this category include paroxetine, citalopram, and sertraline. For dermatitis artefacta associated with obsessive-compulsive disorder, the use of an SSRI for at least 6 months to 1 year accompanied by psychotherapy is recommended.

Fluoxetine (Prozac)

 

Selectively inhibits presynaptic serotonin reuptake with minimal or no effect in reuptake of norepinephrine or dopamine.

May cause more adverse GI effects than other SSRIs currently available, which is the reason it is not recommended as a first choice. May be given as a liquid and a cap.

May give as single dose or in divided doses. Presence of food does not appreciably alter medication levels. May take up to 4-6 wk to achieve steady-state levels because of long half-life (72 h).

Long half-life is both an advantage and a drawback. If it works well, an occasional missed dose is not a problem; if problems occur, eliminating all active metabolites takes a long time. Choice depends on adverse effects and drug interactions. Adverse effects of SSRIs seem to be quite idiosyncratic; thus, if dosing is started at a conservative level and advanced as tolerated, relatively few reasons exist to recommend one over another.

Previous
Next

Tricyclic antidepressants

Class Summary

These agents are used to treat the underlying psychiatric disorder.

Doxepin (Sinequan, Zonalon)

 

Has antihistamine, antipruritic, and antidepressant properties. May be effective for depression (with agitation) and a primary symptom of pruritus.

Increases concentration of serotonin and norepinephrine in CNS by inhibiting their reuptake by presynaptic neuronal membrane, which is associated with a decrease in symptoms of depression.

Amitriptyline (Elavil, Endep)

 

May be effective for depression with primary symptoms of pain sensations (eg, burning, chafing, stinging). Analgesia usually requires doses < 50 mg qhs.

Inhibits reuptake of serotonin and/or norepinephrine at presynaptic neuronal membrane, which increases concentration in CNS. May increase or prolong neuronal activity because reuptake of these biogenic amines is important physiologically in terminating transmitting activity.

Previous
Next

Typical antipsychotics

Class Summary

These agents are used to treat the underlying psychiatric disorder.

Pimozide (Orap)

 

Previously shown to be effective for delusions of parasitosis. Centrally acting dopamine-receptor antagonist. Available in 2-mg scored tab in United States; 2-, 4-, and 10-mg tab available in Canada. Clinical response usually occurs within 10-14 d.

Previous
Next

Atypical antipsychotics

Class Summary

Lower risk of extrapyramidal adverse effects than with typical antipsychotics.

Risperidone (Risperdal)

 

Previously shown to be effective for delusions of parasitosis. Binds to dopamine D2 receptor with 20-times lower affinity than for 5-HT2 receptor. Improves negative symptoms of psychoses and reduces prevalence of extrapyramidal adverse effects. Indicated for treatment of psychotic disorders, including schizophrenia and bipolar disorder. Clinical response usually occurs within 10-14 d.

Olanzapine (Zyprexa)

 

May inhibit serotonin, muscarinic, and dopamine effects. Efficacy similar to risperidone; has fewer dose-dependent adverse effects but is associated with more concern about weight gain.

Quetiapine (Seroquel)

 

May act by antagonizing dopamine and serotonin effects. Efficacy similar to risperidone and olanzapine. Fewer dose-dependent adverse effects and less concern for weight gain.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

John YM Koo, MD  Vice Chair, Department of Dermatology, University of California San Francisco Medical Center; Professor, Clinical Dermatology, Department of Dermatology, University of California at San Francisco School of Medicine

John YM Koo, MD is a member of the following medical societies: American Academy of Dermatology, American Psychiatric Association, and National Psoriasis Foundation

Disclosure: Nothing to disclose.

Coauthor(s)

Patricia T Ting, MD, MSc  Resident Physician, Division of Dermatology and Cutaneous Sciences, Department of Medicine, University of Alberta Faculty of Medicine and Dentistry, Canada

Patricia T Ting, MD, MSc is a member of the following medical societies: Alberta Medical Association, Canadian Dermatology Association, and Canadian Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Jacek C Szepietowski, MD, PhD  Professor, Vice-Head, Department of Dermatology, Venereology and Allergology, Wroclaw Medical University; Director of the Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Poland

Disclosure: Stiefel GSK Company Salary Employment; Orfagen Consulting fee Consulting; Maruho Consulting fee Consulting; Astellas Consulting fee Consulting; Abbott Consulting fee Consulting; Leo Pharma Consulting fee Consulting

David F Butler, MD  Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Edward F Chan, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine

Edward F Chan, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References
  1. Shah KN, Fried RG. Factitial dermatoses in children. Curr Opin Pediatr. Aug 2006;18(4):403-9. [Medline].

  2. Gupta MA, Gupta AK, Ellis CN, Koblenzer CS. Psychiatric evaluation of the dermatology patient. Dermatol Clin. Oct 2005;23(4):591-9. [Medline].

  3. Saez-de-Ocariz M, Orozco-Covarrubias L, Mora-Magana I, et al. Dermatitis artefacta in pediatric patients: experience at the national institute of pediatrics. Pediatr Dermatol. May-Jun 2004;21(3):205-11. [Medline].

  4. Ozmen M, Erdogan A, Aydemir EH, Oguz O. Dissociative identity disorder presenting as dermatitis artefacta. Int J Dermatol. Jun 2006;45(6):770-1. [Medline].

  5. Urpe M, Pallanti S, Lotti T. Psychosomatic factors in dermatology. Dermatol Clin. Oct 2005;23(4):601-8. [Medline].

  6. Sambhi R, Lepping P. Psychiatric treatments in dermatology: an update. Clin Exp Dermatol. Mar 2010;35(2):120-5. [Medline].

  7. Baranska-Rybak W, Cubala WJ, Kozicka D, Sokolowska-Wojdylo M, Nowicki R, Roszkiewicz J. Dermatitis artefacta--a long way from the first clinical symptoms to diagnosis. Psychiatr Danub. Mar 2011;23(1):73-5. [Medline].

  8. Ehsani AH, Toosi S, Shahshahani MM, Arbabi M, Noormohammadpour P. Psycho-cutaneous disorders: an epidemiologic study. J Eur Acad Dermatol Venereol. Mar 11 2009;[Medline].

  9. Ilter N, Adisen E, Gurer MA, Kevlekci C, Tekin O, Sayin A. Dermatitis artefacta masquerading as pyoderma gangrenosum. Int J Dermatol. Sep 2008;47(9):975-7. [Medline].

  10. Harries MJ, McMullen E, Griffiths CE. Pyoderma gangrenosum masquerading as dermatitis artefacta. Arch Dermatol. Nov 2006;142(11):1509-10. [Medline].

  11. Brod CS, Garbe C, Schleicher J, Rocken M, Schilling M. Acquired haemophilia mimicking dermatitis artefacta. Acta Derm Venereol. 2009;89(2):194-5. [Medline].

  12. Angus J, Affleck AG, Croft JC, Leach IH, Slater DN, Millard LG. Dermatitis artefacta in a 12-year-old girl mimicking cutaneous T-cell lymphoma. Pediatr Dermatol. May-Jun 2007;24(3):327-9. [Medline].

  13. Giunta A, Demin F, Campione E, Chimenti S, Bianchi L. Dermatitis artefacta in sporadic sclerodermoid hepatitis C virus-associated porphyria cutanea tarda. J Eur Acad Dermatol Venereol. Dec 22 2008;[Medline].

  14. Cohen AD, Vardy DA. Dermatitis artefacta in soldiers. Mil Med. Jun 2006;171(6):497-9. [Medline].

  15. Koblenzer CS. The current management of delusional parasitosis and dermatitis artefacta. Skin Therapy Lett. Oct 2010;15(9):1-3. [Medline].

  16. Shenefelt PD. Complementary psychocutaneous therapies in dermatology. Dermatol Clin. Oct 2005;23(4):723-34. [Medline].

  17. Gupta MA, Guptat AK. The use of antidepressant drugs in dermatology. J Eur Acad Dermatol Venereol. Nov 2001;15(6):512-8. [Medline].

  18. Lee CS, Koo J. Psychopharmacologic therapies in dermatology: an update. Dermatol Clin. Oct 2005;23(4):735-44. [Medline].

  19. Koblenzer CS. Dermatitis artefacta. Clinical features and approaches to treatment. Am J Clin Dermatol. Jan-Feb 2000;1(1):47-55. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.